Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
4200
¥ million (net sales target for the fiscal year ending March 2029)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedNet SalesNot disclosed → ¥4,200 million
Operating profitNot disclosed → ¥855 million
Net income for the current fiscal yearNot disclosed → ¥578 million
Only the target level is shown because the current level for comparison was not provided.What happened to the previous planConsolidated earnings forecast for the fiscal year ending June 2026 published on 13 August 2025 → Consolidated results for the fiscal year ended June 20260.0%Calculated from the two disclosed figures
Key initiatives
01Stable growth of existing core businesses
02Synchrotron radiation facility-related businesses
03Automated cell culture equipment-related businesses
04Subsidiary-related businesses
05Developing new businesses
06Next-generation processing and polishing equipment-related businesses
07Medical equipment-related businesses
08Optical components and other products related to semiconductors and space
Plan assumptionsInformation currently available to the Company and certain assumptions that it considers reasonable, Subject to approval of the proposed partial amendments to the Articles of Incorporation
Segment targetSegment Optical business / Sales Target Fiscal year ending March 2027 1,100 / Fiscal year ending March 2028 1,800 / Fiscal year ending March 2029 2,100 / Operating profit target Not disclosed, Segment Life Science and Equipment Development business / Sales Target Fiscal year ending March 2027 497 / Fiscal year ending March 2028 1,000 / Fiscal year ending March 2029 1,300 / Operating profit target Not disclosed, Segment Other (電子科学株式会社) / Sales Target Fiscal year ending March 2027 365 / Fiscal year ending March 2028 600 / Fiscal year ending March 2029 800 / Operating profit target Not disclosed
Risks identified by the company
This does not mean that the Company is guaranteeing achievement of this Medium-Term Management Plan
Actual results and other outcomes may differ significantly due to various factors.
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan |
| Plan period | Fiscal years ending March 2027 to March 2029 |
| Progress against the plan | Formulated |
| Sales Target | Not disclosed → ¥4,200 million |
| Operating profit target | Not disclosed → ¥855 million |
| Net income target | Not disclosed → ¥578 million |
| Segment target | Segment Optical business / Sales Target Fiscal year ending March 2027 1,100 / Fiscal year ending March 2028 1,800 / Fiscal year ending March 2029 2,100 / Operating profit target Not disclosed, Segment Life Science and Equipment Development business / Sales Target Fiscal year ending March 2027 497 / Fiscal year ending March 2028 1,000 / Fiscal year ending March 2029 1,300 / Operating profit target Not disclosed, Segment Other (電子科学株式会社) / Sales Target Fiscal year ending March 2027 365 / Fiscal year ending March 2028 600 / Fiscal year ending March 2029 800 / Operating profit target Not disclosed |
| Plan assumptions | Information currently available to the Company and certain assumptions that it considers reasonable, Subject to approval of the proposed partial amendments to the Articles of Incorporation |
| Key initiatives | Stable growth of existing core businesses, Synchrotron radiation facility-related businesses, Automated cell culture equipment-related businesses, Subsidiary-related businesses, Developing new businesses, Next-generation processing and polishing equipment-related businesses, Medical equipment-related businesses, Optical components and other products related to semiconductors and space |
| Results under the previous plan | Consolidated earnings forecast for the fiscal year ending June 2026 published on 13 August 2025 → Consolidated results for the fiscal year ended June 2026 |
| Risks identified | This does not mean that the Company is guaranteeing achievement of this Medium-Term Management Plan, Actual results and other outcomes may differ significantly due to various factors. |
| Publication date | 10 August 2026 |
Items this document does not state (13)
Operating profit margin targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorNon-financial targetsReason for revision or withdrawalSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although the Company's results for the fiscal year ended June 2026 fell substantially short of its published forecast, it considers this an important period in which to transition to Phase 3 of its long-term growth strategy, “Innovation2030.” The Company intends to accelerate its growth rate through stable growth in existing businesses and the full-scale launch of new businesses. It also intends to improve operational efficiency and management transparency by changing its fiscal year-end.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.